US-based compact proton therapy technology company ProTom International on Friday unveiled its new Radiance 330-C Proton Therapy System, a compact and modular proton therapy solution.
The fixed-beam system allows healthcare providers to add single or multiple treatment rooms within existing Linac vaults in radiation oncology departments, reducing overall costs.
Integrated with Leo Cancer Care's upright patient positioning and imaging system, the Radiance 330-C offers gantry-less proton therapy without compromising treatment quality.
It features Fidelity pencil beam scanning technology, enabling precise dose delivery and real-time adaptive therapy.
The system's stationary beam delivery enhances reliability and reduces maintenance, while its compact synchrotron accelerator supports a treatment energy range of 70 MeV to 250 MeV.
ProTom added that the system is not yet available for clinical use.
TheraCryf signs Master Service Agreement with Pharmaron for Orexin-1 addiction programme
AstraZeneca's Imfinzi improves disease-free survival in early bladder cancer trial
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
TransCode Therapeutics reports progress in metastatic cancer trial
Ingenium Therapeutics' Gengleucel to enter Phase 2 trial in MRD+ AML following FDA feedback
AllyGPO and BioCareSD advance community oncology through integrated, tech-driven drug management